John Libbey Eurotext

Hématologie

MENU

Personalised treatment for haemophilia Ahead of print

Figures

  • Figure 1
  • Figure 2
  • Figure 3
Author
1 Clinical Haemostasis Unit, Louis Pradel Cardiology Hospital, Lyon
2 EA4609, Claude Bernard University Lyon 1, Lyon
* Correspondence

Haemophilia treatment has improved tremendously in the past decade with the development of products with extended half-life, non-replacement therapies and the dawn of gene therapy. However, several issues are still open to debate, including the question of which products are appropriate for which patients and at what dosage? Can two procoagulant products be safely combined in the event of severe breakthrough bleeds? Answers to these questions require the adoption of a personalised approach, taking into account variables including genotype, clinical bleeding phenotype, pharmacokinetics, pharmacodynamics, risk associated with inhibitors, joint condition, physical activity, lifestyle and compliance with treatment. This paper discusses scientific data illustrating the importance of these variables as well as clinical, laboratory and radiological tools that may help to optimise treatment of patients with haemophilia.

 
What do you want to do ?
New mail
 
What do you want to do ?
New mail